SEC Filing Summary: Owens & Minor, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2004, for Owens & Minor, Inc. (O&M), a leading distributor of medical and surgical supplies. The filing includes unaudited consolidated financial statements for the three and six months ended June 30, 2004, compared to the same periods in 2003. Note: The input metadata referenced "Accendra Health Inc," but the filing text explicitly identifies the registrant as Owens & Minor, Inc.
Key Financial Metrics
| Metric (in thousands) | Q2 2004 | Q2 2003 | YTD 2004 | YTD 2003 |
|---|---|---|---|---|
| Revenue | $1,119,375 | $1,054,502 | $2,225,449 | $2,072,471 |
| Gross Margin | $114,831 (10.3%) | $108,892 (10.3%) | $228,891 (10.3%) | $215,693 (10.4%) |
| Operating Earnings | $27,654 (2.5%) | $27,419 (2.6%) | $55,092 (2.5%) | $53,995 (2.6%) |
| Net Income | $15,325 | $13,588 | $29,950 | $26,479 |
| Diluted EPS | $0.39 | $0.37 | $0.76 | $0.72 |
| Cash from Operations (YTD) | $71,056 (2004) vs $114,900 (2003) | |||
| Cash & Equivalents (End of Period) | $48,674 | |||
| Long-Term Debt | $207,032 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 6% in Q2 and 7% YTD, driven by new core distribution business (including HealthTrust Purchasing Group) and increased sales to existing customers.
- Profitability: Net income rose 13% in Q2 and 13% YTD. This was driven by higher operating earnings, reduced financing costs, and a lower effective tax rate (37.5% in Q2 2004 vs. 38.9% in 2003).
- Margin Pressure: Operating earnings as a percentage of revenue declined slightly to 2.5% from 2.6% due to competitive pricing pressure, fewer inventory buying opportunities, and increased spending on strategic initiatives (OMSolutions SM).
- Financing Costs: Total financing costs decreased significantly to $3.1 million in Q2 2004 from $5.1 million in Q2 2003, largely due to the repurchase and conversion of mandatorily redeemable preferred securities in 2003.
- Acquisition: In March 2004, O&M acquired 5nQ for $2.5 million in cash to enhance clinical inventory management solutions (QSight SM).
Guidance, Outlook, and Risks
- Strategic Initiatives: Management expects OMSolutions SM expenses to exceed revenue in the near term but anticipates the business will become accretive in the second half of 2004.
- Liquidity: Liquidity remains strong with $48.7 million in cash and $243.5 million of unused credit under an amended revolving credit facility (increased to $250 million, extended to 2009).
- Capital Expenditures: YTD CapEx was $7.7 million. Future spending will focus on a new corporate headquarters and distribution center relocations, while IT spending is expected to remain lower than 2003 levels.
- Risks: Key risks include competitive pricing pressure, dependence on large customers, changes in manufacturer preferences (direct vs. wholesale), and the ability to manage operating expenses while investing in growth.
Investor Verification Checklist
- Verify the sustainability of the 13% net income growth given the slight decline in operating margin percentage.
- Monitor the timeline for OMSolutions SM to become accretive as projected for the second half of 2004.
- Assess the impact of competitive pricing pressure on future gross margins.
- Review the integration progress of the 5nQ acquisition and its contribution to revenue.
- Confirm the stability of accounts receivable collection trends (DSO improved to 25.5 days).